Stock 2181 MABPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Mabpharm Limited Stock

Equities

2181

KYG5780F1046

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 04:08:09 2024-05-16 am EDT 		5-day change 1st Jan Change
0.39 HKD +4.00% Intraday chart for Mabpharm Limited +4.00% -15.22%
Mar. 26 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 10 Livzon Pharma Recognizes Credit, Asset Impairments MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 55.92M 7.75M 60.42M Sales 2023 87.16M 12.07M 94.18M Capitalization 1.72B 239M 1.86B
Net income 2022 -211M -29.23M -228M Net income 2023 -209M -28.95M -226M EV / Sales 2022 30.5 x
Net Debt 2022 123M 17M 133M Net Debt 2023 109M 15.13M 118M EV / Sales 2023 21 x
P/E ratio 2022
-7.52 x
P/E ratio 2023
-8.24 x
Employees 347
Yield 2022 *
-
Yield 2023
-
Free-Float 22.82%
More Fundamentals * Assessed data

Chart Mabpharm Limited

Dynamic Chart

Latest news about Mabpharm Limited

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Livzon Pharma Recognizes Credit, Asset Impairments MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use MT
Mabpharm Limited Announces Director Changes CI
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot MT
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan MT
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy MT
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug MT
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment MT
Mabpharm Limited Announces New Drug Application of CMAB009 CI
Livzon Pharma's COVID vaccine gets approval as booster in China RE
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment MT
More news

Press releases Mabpharm Limited

Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) AQ
Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter AQ
Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021 PU
Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021 PU
Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING PU
More press releases

Quotes and Performance

1 day+4.00%
1 week+4.00%
Current month-2.50%
1 month-8.24%
3 months-17.02%
6 months-11.36%
Current year-15.22%
More quotes

Highs and lows

1 week
0.36
Extreme 0.36
0.39
1 month
0.34
Extreme 0.335
0.45
Current year
0.25
Extreme 0.25
0.50
1 year
0.25
Extreme 0.25
0.79
3 years
0.25
Extreme 0.25
1.40
5 years
0.25
Extreme 0.25
1.80
10 years
0.25
Extreme 0.25
1.80
More quotes

Managers and Directors - Mabpharm Limited

Managers TitleAgeSince
Hao Wang CEO
 Chief Executive Officer 55 18-07-19
Yun Feng Li DFI
 Director of Finance/CFO 47 18-07-19
Tao Jing BRD
 Director/Board Member 51 18-08-02
Members of the board TitleAgeSince
Shu Ge Jiao CHM
 Chairman 58 18-07-19
Ho Ming Leung BRD
 Director/Board Member 41 22-06-16
Wei Zhu Qian FOU
 Founder 48 15-02-03
More insiders

Quotes

Date Price Change Volume
24-05-16 0.39 +4.00% 64,000
24-05-14 0.375 0.00% 0
24-05-13 0.375 0.00% 0
24-05-10 0.375 0.00% 0
24-05-09 0.375 0.00% 0

Delayed Quote Hong Kong S.E., May 16, 2024 at 04:08 am EDT

More quotes

Company Profile

Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.
Sector
Biotechnology & Medical Research
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MABPHARM LIMITED Stock Mabpharm Limited
-15.22% 206M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.29% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 104B
ARGENX SE Stock argenx SE
+0.44% 22.28B
BIONTECH SE Stock BioNTech SE
-11.90% 22.41B
GENMAB A/S Stock Genmab A/S
-4.45% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.36% 18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-5.17% 17.89B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.70% 14.28B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.65% 12.55B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2181 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW